PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 29, 2020Cancer Immunology Immunotherapy280 citationsOpen Access

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

LPLihong PengYWYong WangFLFen Liu

Key Points

Key points are not available for this paper at this time.

Abstract

In patients with advanced NSCLC treated with PD-1 inhibitors, pretreatment NLR, LDH, and PNI may be useful predictive markers of clinical outcome and irAEs.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Peng et al. (2020) studied this question.

synapsesocial.com/papers/69d7e8725c3030ff03d181fchttps://doi.org/10.1007/s00262-020-02585-w
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1[Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients].1984 · 1,733 citations
  2. 2Prognostic nutritional index in gastrointestinal surgery1980 · 1,565 citations
  3. 3Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer2015 · 1,196 citations
  4. 4Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma2014 · 301 citations
  5. 5Cancer statistics in China, 20152016 · 18,017 citations